Fw: e-Newsletter for Friday, March 16, 2012

[Guest guest]

From: "HIVandHepatitis.com" <newsletter@...>Date: Fri, 16 Mar 2012 14:33:32 -0400 (EDT)<nelsonvergel@...>Reply newsletter@...Subject: e-Newsletter for Friday, March 16, 2012Having trouble viewing this email?Click here e-Newsletter for Friday, March 16, 2012 HIV/AIDS Complete Coverage of the 2012 Conference on Retroviruses and Opportunistic Infections HIVandHepatitis.com's complete coverage of the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), March 5-8, 2012. Featuring new HIV drugs, HIV cure research, biomedical prevention, HIV-related conditions and complications, basic science, hepatitis C, and HIV/HCV coinfection. HIV Brain Impairment: Who Gets It, and Why? A number of papers at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle presented advances in research on HIV-related brain impairment and neurocognitive problems. Vorinostat -- A First Step on the Road Towards a Cure for HIV Researchers from the University of North Carolina at Chapel Hill have for the first time shown that HIV can be purged from resting latent T-cells, an important early step in moving research forward on one of the potential HIV cure strategies, according to a report at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Electrocautery Superior to Imiquimod or 5-Fluorouracil for Treatment of Anal Neoplasia Electrocautery was shown to be more effective and tolerable than topical imiquimod or 5-fluorouracil as a treatment for anal intraepithelial neoplasia (AIN) in HIV positive men who have sex with men (MSM), researchers reported in a late-breaker presentation at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Uncontrolled HIV Linked to Faster Lung Function Decline People with detectable HIV viral load and advanced immune deficiency are likely to experience greater decreases in lung function over time, with high viral load linked to more impairment than smoking, according to a study presented last week at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Hepatitis C and HIV/HCV Coinfection Studies Look at Interactions Between New Hepatitis C Drugs and HIV Antiretrovirals Drug-drug interactions between direct-acting antiviral agents for hepatitis C and some antiretroviral medications used to treat HIV are common, but are often modest and can be managed with dose adjustments when treating people with HIV/HCV coinfection, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Forward emailThis email was sent to nelsonvergel@... by newsletter@... | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.HIVandHepatitis.com | 584 Castro Street #272 | San Francisco | CA | 94114